The Best ASX Biotech Stocks
to buy Now In November 2024

Check out our Industry Experts’ report and
analysis on the Best Biotech Stocks right now on the ASX

The Best ASX Biotech Stocks to buy Now In November 2024

Check out our Industry Experts’ report and analysis on the Best Biotech Stocks right now on the ASX

What are Biotech stocks?

ASX biotech stocks alludes to listed companies on the ASX in the biotechnology industry. They are involved in discovering, developing and commercialising drugs and medical devices to fight against or aid with medical conditions. They range from large companies with good sold all over the world like Cochlear and CSL, to smaller companies at the clinical or pre-clinical phases.

Why Invest in ASX Biech Stocks?

Investing in biotech stocks is like having a front hand seat to the future of medicine and making a difference to the health of the population. These companies are often on the cutting edge, developing groundbreaking treatments for a range of illnesses, sometimes even those that have eluded cure for years. When their research hits the mark, the financial rewards can be substantial.

What's more, the biotech sector tends to resilient by the ups and downs of macroeconomic conditions.

Get the Latest Stock Market Insights for Free with
Stocks Down Under & Pitt Street Research

Join our newsletter and receive exclusive insights, market trends, investment tips, and updates delivered directly to your inbox. Don't miss out – subscribe today and make informed investment decisions.

What to look for when investing in Australian Biotech Stocks

When considering biotech stocks, a thoughtful approach is essential. Start by examining the company's research pipeline. What kinds of drug candidates are they developing? Are these diverse and promising? The strength and experience of the management team are also crucial, especially their ability to handle complex clinical trials and regulatory hurdles.

Equally important is the company's financial stability. Biotech firms often require substantial funding for research and development, so robust financial health is a key indicator of their potential for success. Regulatory milestones are significant influencers of stock value and should be monitored closely. Also, assess the market demand for their products and the competitive landscape.

And although nothing compares to regulatory approval, other feats can be achieved prior to clinical trial success that can set a company up for bright future including obtaining Orphan Drug Status, a Priority Review Voucher or licensing deals.

The Future Outlook of the ASX Biotechnology Sector

We expect the Australian biotechnology sector to enter a new exciting era in the coming months. A key driver of this upswing is the expected reduction in interest rates, which traditionally boosts investment into biotechs, among other small caps.

Another will be the so-called 'patent cliff' that will occur over the rest of the decade. Morgan Stanley predicts that by 2030, the products that will lose exclusivity over this time generate $183.5m in annual sales right now. This will make it easier for companies to enter markets as they will be able to compete directly as opposed to having to find an indication without drugs and have their own market exclusivity for a time.

3 Best ASX Biotech Stocks to Buy Now in 2024

CSL (ASX:CSL)

CSL is the largest biotech stock on the ASX, as well as one of the ASX's 5 largest companies - capped at over $150bn. It is best known for its flu vaccine and blood plasma businesses although has a significant R&D pipeline including the Vifor business is bought in 2021.

Dimerix (ASX:DXB)

Dimerix is developing a drug against a kidney condition known as FSGS. It is currently in a Phase 3 trial which is the last step before it can be commercialised, and interim results in March 2024 show positive results so far. Data is expected in mid CY25. And although it has already secured US$300m worth of licensing deals, the US and China remain unlicensed and this could be another catalyst in the months ahead.

Opthea (ASX:OPT)

Opthea is developing a drug called Sozinibercept (formerly known as OPT-302) and is in Phase 3 for wet AMD, with results due in the first half of CY25. Wet AMD is the leading cause of blindness, impacting 3.5m people annually across the globe. Opthea reckons it has a US$15bn market based off the sales for all its competitors. And when it is approved, Sozinibercept could have up to 12-year market exclusivity.

3 Best ASX Biotech Stocks to Buy Now in 2024

CSL (ASX:CSL)

CSL has two primary businesses: flu vaccines and blood products – it takes plasma from donors and turns it into life-saving therapeutics, particularly immunoglobin products. Plasma is the substance that carries red and white blood cells through the body – these therapies are relevant for disorders such as hemophilia, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.

CSL was once a government entity, established in 1916. It was privatised in 1994 at $2.30 a share, although it undertook a three for one share split in 2007 making its IPO price 76.7c in real terms, meaning it has been more than a 300-bagger since listing!

The company has a long R&D pipeline that grew substantially after the 2021 acquisition of Switzerland’s Vifor Pharma, which cost US$11.7bn.

And it had some exciting catalysts to come including earnings from Vifor and the potential FDA approval of Hemgenix (the world’s first gene therapy for haemophilia B). The company has told investors to expect 'double digits earnings growth' over the rest of the decade.

Dimerix (ASX:DXB)

Dimerix is focused on kidney disease. Its flagship asset DMX-200 is targeting a condition known as Focal Segmental Glomerulosclerosis (FSGS).

When you have FSGS, the filters (glomeruli) of your kidneys become inflamed and are damaged by scarring. This makes the filters “leaky” and allows protein from your blood to collect in your urine (proteinuria). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can lead to kidney failure that may eventually requires dialysis or a kidney transplant.

The company is currently in a Phase 3 trial and interim results in March 2024 led to a significant re-rating of shares. Data is expected in mid CY25. And although it has already secured US$300m worth of licensing deals, the US and China remain unlicensed and this could be another catalyst in the months ahead.

Opthea (ASX:OPT)

Opthea is developing a drug called Sozinibercept (formerly known as OPT-302) and is in Phase 3 for wet AMD, with results due in the first half of CY25.

Wet AMD is the leading cause of blindness, impacting 3.5m people annually across the globe. Opthea reckons it has a US$15bn market based off the sales for all its competitors. And when it is approved, Sozinibercept could have up to 12-year market exclusivity.

Pros and Cons of Investing in Biotech Stocks ASX

The pros include the biotech sector's resilience to economic conditions, positive ESG angles from helping societal challenges, the 'so-called patent cliff' and the push for innovative healthcare solutions.

The latter is being aided by government initiatives aimed to promote the growth of biotech companies. These initiatives aim to simplify the process of bringing new products to market, from streamlining regulatory pathways to standardizing clinical studies, thereby accelerating product approvals.

However, the biotech sector's complexity poses a challenge for investors without an appropriate risk appetite or without medical or scientific background. For companies still at the clinical stage, there is the risk that a drug will not make it to market. It can be difficult to evaluate the potential of biotech products and their likelihood of success in the market, adding layers of uncertainty to investment decisions.

The journey to market for biotech products, especially those targeting rare diseases, is fraught with challenges. Each step, from clinical trials to regulatory approvals, carries the risk of failure. If a drug fails to get approval or a company reports unfavourable trial results, share prices can plummet swiftly, highlighting the high-risk nature of biotech investments.

How to Choose the Right ASX Biotech Shares?

Selecting the perfect ASX biotech stock requires thorough research, a dose of patience, and a knack for spotting future winners. Start by diving deep into the company's research activities. Are they working on diverse and groundbreaking medical treatments? Check their history: how well do they maneuver through the maze of clinical trials and regulatory approvals? Stable finances are key, as these companies often burn through cash for research before making a dime.

Also, gauge the market's appetite for their innovations and the competition they face. Remember, biotech investing is not for the faint-hearted. It's a high-stakes game with long product development timelines and potential regulatory hurdles.

Success in this sector often comes from backing those innovators who are not just dreaming up futuristic medical solutions, but also possess the smarts to bring these dreams to life in the market.

Are ASX Biotech Stocks right for you?

Deciding whether ASX biotech stocks are right for you hinges on your investment profile and risk tolerance. These stocks offer the thrilling possibility of being part of groundbreaking medical advancements, potentially yielding substantial returns.

However, they're not without their risks - the long and uncertain road to product development and regulatory approvals can be daunting.

If you're the type who relishes the idea of investing in cutting-edge medical research with the potential for high rewards, and you're comfortable with the accompanying volatility and long-term commitment, then biotech stocks might be a fitting addition to your portfolio. But if stability and predictability are more your style, you might want to look elsewhere.

FAQs on Investing in Biotech Stocks

What are ASX Biotech Stocks?

ASX Biotech Stocks are shares of companies in the Australian biotechnology sector, engaged in medical, agricultural, or environmental technology using biological systems. These companies focus on innovative healthcare solutions, including drug development and genetic research.

Why Invest in ASX Biotech Stocks?

What Risks are Associated with ASX Biotech Stocks?

How to Choose the Right ASX Biotech Stocks?

Are Dividends Common in ASX Biotech Stocks?

What are the best ASX Biotech Stocks